Respiratory Disease

Optimise drug treatments supporting patients with lung disease and respiratory problems

Common forms of lung disease such as asthma, emphysema, chronic obstructive pulmonary disorder and chronic bronchitis affect large populations globally and are caused by a combination of genetic, environmental and lifestyle factors. The main risk factor for COPD, which is believed to affect 5% of the population globally, is smoking. Although there are effective therapies to treat this and associated diseases such as emphysema and chronic bronchitis, patients are often non-compliant with both taking their medication and following lifestyle advice. Research Partnership has conducted significant research with patients and physicians to understand compliance, and has had success using mobile methodologies to gather in-the-moment insights into patient behaviour. We can also help you with:  

  • Opportunity and demand assessment

  • Understanding the global and local market opportunity

  • Segmenting the market

  • Product and portfolio development

  • Brand positioning, launch and beyond 

Syndicated services

Living with Eosinophillic & Severe Asthma

We offer a syndicated report based on quantitative research with patients in 2EU, US & Japan, which provides valuable insights into patients' emotions, attitudes, behaviours, treatments and unmet needs.

This research can be used to understand: 

  • The diagnosis pathway and patient journey of patients with severe asthma
  • Reasons for delay in treatment initiation
  • Level of satisfaction with current treatment
  • Awareness of new products


Asthma in EM case study Sept 2019

Case study

How we helped assess the asthma market landscape in emerging markets.

Learn More

inhale exhale small


Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma.

Find out more